Work

Investigating the role of the Notch atypical ligand, delta-like homologue 1 (DLK1) in adrenocortical carcinoma

Year: 2023
Type: dissertation
Study design: Observational Study
Abstract: Adrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options and a heterogenous prognosis. The histological diagnosis of ACC is complex and there is increasing interest in identifying and validating new immunohistochemical markers. Delta-like non-canonical Notch ligand 1 (DLK1) is a cleavable single-pass transmembrane protein. In humans, DLK1 is present in many tissues during foetal development, is restricted to progenitor/stem cells in a few adult tissues but is expressed in numerous malignancies. To study DLK1 expression in ACC, samples were collected in a discovery cohort of patients undergoing adrenalectomy in London. Immunohistochemical expression and pre-operative serum levels of DLK1 were statistically significantly raised in patients with ACC compared with other pathology. To further interrogate the prognostic significance and associated clinical and histopathological features of DLK1 expression in ACC, a validation cohort of 178 samples was studied. Higher immunohistochemical expression of DLK1 (versus lower, across the median) was proven to be an independent risk factor for both disease recurrence and progression in multivariate Cox regression analyses. DLK1 expression was also found in a novel mice model of ACC where higher levels are associated with increased malignancy, recapitulating the picture seen in human disease. After initial identification through a proteomic approach in the ACC cell line, H295R, DLK1 was proven to interact with the actin motor protein non-muscle myosin IIa (NMMIIa) in adrenocortical carcinoma tissue. Expression of NMMIIa was studied in 96 ACC tumour samples and higher expression was shown to worsen survival metrics when combined with DLK1 expression data. The data presented suggest that DLK1 expression is a disease defining event in ACC and that it may drive malignancy. In addition, DLK1 serum levels, in combination with immunohistochemical expression in tumours, may provide a clinically useful novel biomarker for the diagnosis and monitoring of ACC.
Author: Pittaway, J
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: green
OpenAlex ID: W7001301952
Cites: 146
Cited by:
Related to: 10